Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
group A and C meningococcal polysaccharide conjugate vaccine (Shanxi Center for Disease Control and Prevention)
- Development stage
- Unknown
- Lead developer
- Beijing Zhifei Lvzhu Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The group A and C meningococcal polysaccharide conjugate vaccine is a bivalent biologic designed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A and C. It consists of capsular polysaccharides from these serogroups chemically conjugated to a carrier protein, such as tetanus toxoid or diphtheria toxoid, to enhance immunogenicity and induce T-cell dependent immune responses, which are particularly effective in infants and young children. This vaccine has been evaluated in clinical trials, including Phase 4 re-registration studies in China conducted by the Shanxi Provincial Center for Disease Control and Prevention, where it was assessed for safety, immunogenicity, and persistence when administered as a multi-dose primary series with a booster.
- Other names
- Group A and C meningococcal polysaccharide conjugate vaccineMenAC conjugate vaccineBivalent meningococcal (A and C) conjugate vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on group A and C meningococcal polysaccharide conjugate vaccine (Shanxi Center for Disease Control and Prevention).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on group A and C meningococcal polysaccharide conjugate vaccine (Shanxi Center for Disease Control and Prevention).